Bio Techne Corp Stock Current Liabilities
| TECH Stock | USD 63.49 1.96 3.19% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Bio Techne's long-term financial health and intrinsic value.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Bio Techne Corp Company Current Liabilities Analysis
Bio Techne's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Bio Techne Current Liabilities | 54.15 M |
Most of Bio Techne's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bio Techne Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, Bio Techne Corp has a Current Liabilities of 54.15 M. This is 96.91% lower than that of the Life Sciences Tools & Services sector and 90.03% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.31% higher than that of the company.
Bio Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bio Techne's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bio Techne could also be used in its relative valuation, which is a method of valuing Bio Techne by comparing valuation metrics of similar companies.Bio Techne is currently under evaluation in current liabilities category among its peers.
Bio Fundamentals
| Return On Equity | 0.038 | |||
| Return On Asset | 0.0609 | |||
| Profit Margin | 0.06 % | |||
| Operating Margin | 0.15 % | |||
| Current Valuation | 9.84 B | |||
| Shares Outstanding | 155.81 M | |||
| Shares Owned By Insiders | 0.28 % | |||
| Shares Owned By Institutions | 99.72 % | |||
| Number Of Shares Shorted | 7.59 M | |||
| Price To Earning | 74.38 X | |||
| Price To Book | 4.88 X | |||
| Price To Sales | 7.88 X | |||
| Revenue | 1.22 B | |||
| Gross Profit | 813.2 M | |||
| EBITDA | 216.88 M | |||
| Net Income | 73.4 M | |||
| Cash And Equivalents | 247.03 M | |||
| Cash Per Share | 6.30 X | |||
| Total Debt | 444.06 M | |||
| Debt To Equity | 0.19 % | |||
| Current Ratio | 3.44 X | |||
| Book Value Per Share | 12.62 X | |||
| Cash Flow From Operations | 287.56 M | |||
| Short Ratio | 3.32 X | |||
| Earnings Per Share | 0.49 X | |||
| Price To Earnings To Growth | 0.85 X | |||
| Target Price | 69.17 | |||
| Number Of Employees | 3.1 K | |||
| Beta | 1.47 | |||
| Market Capitalization | 9.59 B | |||
| Total Asset | 2.56 B | |||
| Retained Earnings | 1.07 B | |||
| Working Capital | 432.45 M | |||
| Current Asset | 253.89 M | |||
| Current Liabilities | 54.15 M | |||
| Annual Yield | 0.01 % | |||
| Five Year Return | 0.56 % | |||
| Net Asset | 2.56 B | |||
| Last Dividend Paid | 0.32 |
About Bio Techne Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bio Techne Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Techne using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Techne Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Bio Techne Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Techne's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Techne Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Techne Corp Stock:Check out Bio Techne Piotroski F Score and Bio Techne Altman Z Score analysis. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Techne. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Techne listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bio Techne Corp is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Techne's value that differs from its market value or its book value, called intrinsic value, which is Bio Techne's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Techne's market value can be influenced by many factors that don't directly affect Bio Techne's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Techne's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Techne is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Techne's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.